GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.
Company profile
Ticker
GOVX, GOVXW
Exchange
Website
CEO
David Dodd
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DAUPHIN TECHNOLOGY INC
SEC CIK
Corporate docs
Subsidiaries
GeoVax, Inc. • Immutak Oncology, Inc. ...
IRS number
870455038
GOVX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
GeoVax Reports 2023 First Quarter Financial Results
5 May 23
424B3
Prospectus supplement
4 May 23
424B3
Prospectus supplement
4 May 23
424B3
Prospectus supplement
4 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K/A
2022 FY
Annual report (amended)
27 Apr 23
EFFECT
Notice of effectiveness
27 Mar 23
EFFECT
Notice of effectiveness
27 Mar 23
EFFECT
Notice of effectiveness
27 Mar 23
8-K
GeoVax Reports 2022 Year-End Financial Results
24 Mar 23
Transcripts
GOVX
Earnings call transcript
2022 Q4
23 Mar 23
GOVX
Earnings call transcript
2022 Q3
10 Nov 22
GOVX
Earnings call transcript
2022 Q2
3 Aug 22
GOVX
Earnings call transcript
2022 Q1
28 Apr 22
GOVX
Earnings call transcript
2021 Q4
10 Mar 22
GOVX
Earnings call transcript
2021 Q3
12 Nov 21
GOVX
Earnings call transcript
2021 Q2
12 Aug 21
GOVX
Earnings call transcript
2021 Q1
9 May 21
GOVX
Earnings call transcript
2020 Q4
24 Mar 21
GOVX
Earnings call transcript
2020 Q3
8 Nov 20
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 23.85 mm | 23.85 mm | 23.85 mm | 23.85 mm | 23.85 mm | 23.85 mm |
| Cash burn (monthly) | 1.25 mm | (no burn) | 1.42 mm | 1.32 mm | 1.25 mm | 1.54 mm |
| Cash used (since last report) | 2.80 mm | n/a | 3.18 mm | 2.96 mm | 2.80 mm | 3.44 mm |
| Cash remaining | 21.05 mm | n/a | 20.67 mm | 20.89 mm | 21.05 mm | 20.41 mm |
| Runway (months of cash) | 16.8 | n/a | 14.5 | 15.8 | 16.8 | 13.3 |
Institutional ownership, Q4 2022
9.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 23 |
| Opened positions | 3 |
| Closed positions | 5 |
| Increased positions | 7 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 952.43 mm |
| Total shares | 2.59 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 730.99 k | $460.67 mm |
| BLK Blackrock | 413.44 k | $260.55 mm |
| Renaissance Technologies | 410.46 k | $259.00 k |
| Cavalry Fund I Management | 219.34 k | $1.01 mm |
| Geode Capital Management | 172.75 k | $108.00 k |
| STT State Street | 168.14 k | $105.96 mm |
| Bigger Capital Fund L P | 151.12 k | $511.00 k |
| CVI | 68.00 k | $10.20 mm |
| Susquehanna International | 58.55 k | $28.45 mm |
| MS Morgan Stanley | 57.28 k | $36.10 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 24 Apr 23 | David A Dodd | Common Stock | Buy | Acquire P | No | No | 0.6389 | 32,000 | 20.44 k | 113,870 |
| 20 Apr 23 | Mark Reynolds | Common Stock | Buy | Acquire P | No | No | 0.63 | 8,000 | 5.04 k | 68,184 |
| 21 Sep 22 | Randal D Chase | Common Stock | Buy | Acquire P | No | No | 1.1 | 10,000 | 11.00 k | 36,613 |
News
2 Cases Of Mpox Detected In Beijing
6 Jun 23
GeoVax Partners With ABL To Advance cGMP Production Of Vaccine Candidates
31 May 23
GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results
24 May 23
Report of Mpox Cases Rising in Vaccinated People In Chicago, France
12 May 23
Noble Capital Markets Initiates Coverage On Geovax Labs with Outperform Rating, Announces Price Target of $6
8 May 23
Press releases
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
31 May 23
GeoVax to Participate in Upcoming Industry Meetings
25 May 23
GeoVax's Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
24 May 23
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
4 May 23
GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host
26 Apr 23